drugset / Trial / NCT03090503
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
Phase 4
Unknown
200 enrolled
Fundación Marques de Valdecilla
Centro de Investigación Biomédica en Red de Salud Mental · collabInstituto de Investigación Marqués de Valdecilla · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an assistance program of early-stage psychosis individuals of the Community of Cantabria, clinical reference for the treatment of this disease in the Spanish Autonomous Community. Patients are included in a prospective naturalistic study, open flexible-doses and randomized into one of two possible patterns of treatment that includes the protocol.
Timeline
- Start
- 2014-06
- Primary completion
- 2019-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 30 mg | Oral |
| Comparator | Risperidone | Other / unclassified | 1 mg | Oral |
| Comparator | Risperidone | Other / unclassified | 6 mg | Oral |